Allergic Rhinitis Drugs Market forecast 2016 2026
•
0 likes•39 views
For a report overview of this report please contact sara.peerun@visiongainglobal.com (+44 (0) 20 7336 6100) or refer to our website: http://www.visiongain.com/blog/pha0142-ss
Recommended
Recommended
More Related Content
Recently uploaded
Recently uploaded (20)
Featured
Featured (20)
Allergic Rhinitis Drugs Market forecast 2016 2026
- 1. ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only. Allergic Rhinitis Drugs Market Forecast 2016-2026 Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co.
- 2. www.visiongain.com Contents 1. Report Overview 1.1 Global Allergic Rhinitis Drugs: Market Overview 1.2 Global Allergic Rhinitis Drugs Market Segmentation 1.3 Overview of Findings 1.4 Structure of the Report 1.5 Why You Should Read This Report 1.6 How This Report Delivers 1.7 Key Questions Answered by This Analytical Report 1.8 Who is This Report For? 1.9 Methodology 1.10 Frequently Asked Questions (FAQ) 1.11 Associated Visiongain Reports 1.12 About Visiongain 2. An Introduction to Allergic Rhinitis Drugs 2.1 The Pharmaceutical Industry: A Brief Introduction 2.1.1 Allergic Rhinitis Treatments – An Industry Overview 2.2 A Brief Overview of Allergy 2.3 Allergic Rhinitis 2.3.1 The Global Prevalence of Allergic Rhinitis 2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells 2.3.3 Symptoms of Allergic Rhinitis 2.3.4 Classification of Allergic Rhinitis 1. Report Overview 2. An Introduction to Allergic Rhinitis Drugs
- 3. www.visiongain.com Contents 2.3.4.1 Non-Allergic Rhinitis and Mixed Rhinitis 2.3.5 Seasonal Allergic Rhinitis (Hay Fever) 2.3.6 Perennial Allergic Rhinitis 2.3.7 Diagnosis of Allergic Rhinitis 2.4 Treatment of Allergic Rhinitis 2.4.1 Antihistamines 2.4.1.1 First-Generation Antihistamines 2.4.1.2 Second- And Third-Generation Antihistamines 2.4.2 Corticosteroids 2.4.2.1 First-, Second- And Third-Generation Intranasal Corticosteroids 2.4.2.2 Combination Drug Products 2.4.3 Leukotriene Receptor Antagonists 2.4.4 Cromolyn (cromoglicic acid) 2.4.5 Decongestants 2.4.6 Saline Nasal Sprays 2.4.7 Immunotherapy and Vaccines 2.5 Phases of Clinical Trials 2.6 Scope of this Report 3. The Global Allergic Rhinitis Drugs Market, 2016-2026 3.1 The Global Allergic Rhinitis Drugs Market: Market Overview 3.2 Categorisation Of The Global Allergic Rhinitis Drugs Market 3.3 The Global Allergic Rhinitis Drugs Market in 2015 3.4 The Global Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 3. The Global Allergic Rhinitis Drugs Market, 2016-2026
- 4. www.visiongain.com Contents 3.5 Allergic Rhinitis Drugs: Changing Market Shares by Sector 2016-2026 4. Oral Antihistamines Market: Market Analysis And Forecast 2016-2026 4.1 Oral Antihistamines: Market Overview 4.1.1 Leading Products in the Oral Antihistamines Market, 2015 4.2 Oral Antihistamines: Market Trends and Developments, 2016 4.2.1 Patent Expiries and the Threat of Generics 4.2.2 The Increasing Switch from Prescription to Over-The-Counter Sales 4.2.3 The Potential for Combination Therapy with Intranasal Corticosteroids 4.3 Oral Antihistamines: Market Forecast 2016-2026 4.3.1 Oral Antihistamines: Changing Market Shares by Leading Drugs 2016-2026 4.4 Leading Oral Antihistamines for the Treatment of Allergic Rhinitis 4.4.1 Allegra/Allegra-D/Allegra OTC (fexofenadine) - Sanofi 4.4.1.1 Allegra/Allegra OTC: Historical Sales, 1995-2014 4.4.1.2 Allegra/Allegra OTC: Sales Forecast 2015-2026 4.4.2 Claritin/Claritin OTC (loratadine) – Bayer/ Merck & Co 4.4.2.1 Claritin/Claritin OTC: Sales Forecast 2016-2026 4.4.3 Zyrtec/Zyrtec D (cetirizine) - Johnson & Johnson/ UCB/ GSK 4.4.3.1 Zyrtec/Zyrtec D: Sales Forecast 2016-2026 4.4.5 Xyzal (levocetirizine) - Sanofi/ UCB/ GSK 4.4.5.1 Xyzal: Sales Forecast 2016-2026 4.4.6 Clarinex (desloratadine) - Merck & Co. 4.4.6.1 Clarinex: Sales Forecast 2016-2026 4.4.7 Allelock (olopatadine) - Kyowa Hakko Kirin 4. Oral Antihistamines Market: Market Analysis and Forecast, 2016-2026
- 5. www.visiongain.com Contents 4.4.7.1 Allelock: Sales Forecast 2016-2026 4.4.8 Ebastel (ebastine) - AstraZeneca/Takeda/Dainippon Sumitomo 4.4.8.1 Ebastel: Sales Forecast 2016-2026 4.4.9 Talion (bepotastine) - Mitsubishi Tanabe 4.4.9.1 Talion: Sales Forecast 2016-2026 4.4.10 Other Oral Antihistamines: Sales Forecast 2016-2026 5. Intranasal Corticosteroids Market: Market Analysis and Forecast 2016-2026 5.1 Leading Products in the Intranasal Corticosteroids Market, 2015 5.2 Intranasal Corticosteroids: Market Forecast 2016-2026 5.2.1 Intranasal Corticosteroids: Changing Market Shares By Leading Drugs 2016-2026 5.3 Leading Intranasal Corticosteroids 5.3.1 Flixonase/Flonase/Flonase-OTC (fluticasone propionate) - GlaxoSmithKline 5.3.1.1 Flixonase/Flonase/Flonase-OTC Forecast, 2016-2026 5.3.2 Nasonex (mometasone) - Merck 5.3.2.1 Nasonex Forecast, 2016-2026 5.3.3 Avamys/Veramyst (fluticasone furoate) - GlaxoSmithKline 5.3.3.1 Avamys/Veramyst Forecast, 2016-2026 5.3.4 Rhinocort (budesonide) - AstraZeneca 5.3.4.1 Rhinocort Forecast, 2016-2026 5.3.5 Nasacort/Nasacort-OTC (triamcinolone) - Sanofi 5.3.5.1 Nasacort/Nasacort-OTC Forecast, 2016-2026 5.3.6 Omnaris (ciclesonide) - Dainippon Sumitomo/Takeda 5. Intranasal Corticosteroids Market: Market Analysis and Forecast, 2016- 2026
- 6. www.visiongain.com Contents 5.3.6.1 Omnaris: Sales Forecast, 2016-2026 5.3.7 Beconase/Beconase AQ (beclometasone) - GlaxoSmithKline/Omega Pharma 5.3.7.1 Beconase/Beconase AQ Forecast, 2016-2026 5.3.8 Qnasl (beclometasone) - Teva 5.3.8.1 Qnas Forecast, 2016-2026 5.3.9 Zetonna (ciclesonide) - Dainippon Sumitomo 5.3.9.1 Zetonna Forecast, 2016-2026 6. Immunotherapy and Vaccines: Market Analysis and Forecast 2016-2026 6.1 Immunotherapy and Vaccines: Market Overview 6.1.1 Immunotherapy: Primed for Rapid Expansion 6.2 Leading Immunotherapy Products in the Allergic Rhinitis Market, 2015 6.3 Allergic Rhinitis Immunotherapy: Market Trends and Developments, 2016 6.3.1 Subcutaneous and Sublingual Immunotherapy 6.3.2 Expansion into the US Market 6.3.3 Standardisation of Immunotherapy Products 6.3.4 Immunotherapy as a Preventative Treatment 6.4 Allergic Rhinitis Immunotherapy: Market Forecast 2016-2026 6.4.1 Allergic Rhinitis Immunotherapy: Changing Market Shares by Leading Products 2016- 2026 6.5 Immunotherapy Type – By Route of Administration, 2015 6.6 Leading Immunotherapy Products for Allergic Rhinitis 6.6.1 Staloral (Grass pollen allergen extract) - Stallergenes 6.6.1.1 Staloral: Sales Forecast 2016-2026 6. Immunotherapy and Vaccines: Market Analysis and Forecast, 2016-2026
- 7. www.visiongain.com Contents 6.6.2 Alutard SQ (Grass pollen allergen extract) - ALK-Abelló 6.6.2.1 Alutard SQ: Sales Forecast 2016-2026 6.6.3 Grazax/Grastek (Timothy grass pollen allergen extract) - ALK-Abelló/Merck 6.6.3.1 Grazax/Grastek: Sales Forecast 2016-2026 6.6.4 Oralair (Grass pollen allergen extract) - Stallergenes/Greer 6.6.4.1 Oralair: Sales Forecast 2016-2026 6.6.5 Ragwitek (Short ragweed pollen allergen extract) - Merck 6.6.5.1 Ragwitek: Sales Forecast 2016-2026 6.6.6 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2016-2026 7. The Intranasal Antihistamines Market: Market Analysis and Forecast 2016-2026 7.1 Leading Products in the Intranasal Antihistamines Market, 2015 7.2 Intranasal Antihistamines: Market Trends and Developments, 2016 7.3 Intranasal Antihistamines: Market Forecast 2016-2026 7.4 Leading Intranasal Antihistamines 7.4.1 Dymista (azelastine/fluticasone) - Meda Pharmaceuticals 7.4.1.1 Mylan Acquires Meda Pharmaceuticals 7.4.1.2 Dymista: Sales Forecast 2016-2026 7.4.2 Generic Intranasal Azelastine 7.4.2.1 Generic Intranasal Azelastine: Sales Forecast, 2016-2026 7.4.3 Astepro (azelastine) – Meda Pharmaceuticals 7.4.3.1 Astepro: Sales Forecast 2016-2026 7.4.4 Patanase (olopatadine) - Novartis 7. The Intranasal Antihistamines Market: Market Analysis and Forecast, 2016-2026
- 8. www.visiongain.com Contents 7.4.4.1 Patanase: Sales Forecast 2016-2026 7.4.5 Astelin (azelastine) - Meda Pharmaceuticals 7.4.5.1 Astelin: Sales Forecast 2016-2026 8. Leading National Markets for Allergic Rhinitis Drugs, 2016-2026 8.1 The Allergic Rhinitis Drugs Market by Region 8.1.1 The Global Distribution of Allergic Rhinitis Drugs in 2015 8.2 Leading National Markets: Forecast 2016-2026 8.2.1 Changing Market Shares by Region, 2016-2026 8.3 Regional Allergic Rhinitis Drugs Markets: Analysis and Forecasts, 2016-2026 8.3.1 United States: The Largest Allergic Rhinitis Drugs Market 8.3.1.1 US Allergic Rhinitis Drugs Market: Trends and Developments 8.3.1.1.1 The Trend of Rx-to-OTC Switching 8.3.1.2 US Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.3.2 EU5 8.3.2.1 EU5 Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.3.2.2 EU5 Markets: Changing Market Shares by Country, 2016-2026 8.3.2.3 Germany 8.3.2.3.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law 8.3.2.3.2 German Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.3.2.4 UK 8.3.2.4.1 UK: Increasing Burden of Allergy 8.3.2.4.2 UK Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.3.2.5 France 8.3.2.5.1 France: Social Security Finance Act 2015 8. Leading National Markets for Allergic Rhinitis Drugs, 2016-2026
- 9. www.visiongain.com Contents 8.3.2.5.2 French Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.3.2.6 Italy 8.3.2.6.1 Italy: Government Cost Cutting Measures Impacting Market Growth 8.3.2.6.2 Italian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.3.2.7 Spain 8.3.2.7.1 Spanish Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.6 China 8.6.1 Air Pollution Associated With Increasing Prevalence 8.6.2 Expansion of Healthcare Coverage and Reimbursement in China 8.6.3 Chinese Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.7 Japan 8.7.1 Cedar Reforestation and the Hay Fever Epidemic 8.7.2 Genetically Modified Rice as Immunotherapy 8.7.3 Effects of the Rising Levels of Generic Drug Penetration 8.7.4 Japanese Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.8 Russia 8.8.1 How Will Russia’s Economic Status Affect Its Pharma Industry? 8.8.2 Russian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.9 India 8.9.1 The Impact of the Drug Prices Control Order on Indian Pharma 8.9.2 India’s Expansion of Healthcare Provision 8.9.3 Indian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 8.10 Brazil 8.10.1 How Will Brazil’s Growing Healthcare Influence Allergic Rhinitis Drugs 8.10.2 Brazilian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026
- 10. www.visiongain.com Contents 8.12 Rest of the World 8.12.1 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 9. Leading Companies in the Allergic Rhinitis Drugs Market, 2016-2026 9.1 Allergic Rhinitis Drugs – An Evolving Market Space 9.1.1 Leading Companies in the Allergic Rhinitis Drugs Market, 2016 9.2 ALK-Abelló 9.2.1 ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2016 9.2.2 ALK-Abelló: Recent Developments 9.2.2.1 Acarizax Launched in Europe progressing to International Roll-Out 9.2.2.2 ALK Collaborates With EddingPharm to Boost China Sales 9.2.2.3 ALK-Abelló: Sales Forecast 2016-2026 9.2.2.4 ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2016 9.3 GlaxoSmithKline (GSK) 9.3.1 GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2016 9.3.2 GlaxoSmithKline: Sales Forecast 2016-2026 9.4 Johnson & Johnson 9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2016 9.4.2 Johnson & Johnson: Recent Developments 9.4.2.1 Manufacturing Recalls At McNeil Consumer Healthcare 9.4.2.2 Johnson & Johnson: Sales Forecast 2016-2026 9.5 Kyowa Hakko Kirin 9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2015 9.5.2 Kyowa Hakko Kirin: Sales Forecast 2016-2026 9. Leading Companies in the Allergic Rhinitis Drugs Market, 2016-2026
- 11. www.visiongain.com Contents 9.6 Merck & Co. 9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2016 9.6.2 Merck: Recent Developments 9.6.2.1 Bayer Acquires Merck’s Consumer Health Business 9.6.2.2 FDA Rejects Singulair OTC Switch 9.2.6.3 Merck: Sales Forecast 2016-2026 9.2.6.4 Merck: Allergic Rhinitis Drug Development Pipeline, 2016 9.7 Sanofi 9.7.1 Sanofi: Allergic Rhinitis Drugs Portfolio, 2016 9.7.2 Sanofi: Sales Forecast 2016-2026 9.8 Stallergenes Greer 9.8.1 Stallergenes: Allergic Rhinitis Drugs portfolio, 2015 9.8.2 Stallergenes Greer: Sales Forecast 2016-2026 9.8.3 Stallergenes Greer: Allergic Rhinitis Drug Development Pipeline, 2015 9.9 UCB 9.9.1 UCB: Allergic Rhinitis Drugs Portfolio, 2015 9.9.2 UCB: Sales Forecast 2016-2026 9.10 Other Leading Companies within the Allergic Rhinitis Drugs Market 10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2016-2026 10.1 Trends and Developments in the Allergic Rhinitis Pipeline 10.2 The R&D Pipeline for Oral Antihistamines, 2016 10.2.1 Talion (bepotastine) - Mitsubishi Tanabe 10.2.2 ZPL-3893787 (histamine H4R antagonist) - Ziarco Pharma 10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2016-2026
- 12. www.visiongain.com Contents 10.3 The R&D Pipeline for Intranasal Corticosteroids, 2016 10.3.1 APC-3000 (HFA inhaled corticosteroid) - Adamis Pharmaceuticals 10.3.2 TBS-6 - Trimel Pharmaceuticals 10.4 The R&D Pipeline for Immunotherapy in Allergic Rhinitis, 2016 10.4.1 Actair (house dust mite SLIT; STG320) - Stallergenes/Shionogi & Co 10.4.2 AllerT (subcutaneous birch pollen immunotherapy) - Anergis 10.4.3 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma 10.4.4 House Dust Mite SLIT-Tablet (MK-8237) - ALK-Abelló/Merck/Torii 10.4.5 Pollinex Quattro (subcutaneous immunotherapies) - Allergy Therapeutics 10.4.6 gp-ASIT+ (grass pollen allergen fragments) - Biotech Tools 10.4.7 Betula verrucosa (Bet v) 1 allergen – Stallergenes Greer 10.5 The R&D Pipeline for Other Allergic Rhinitis Drugs 10.5.1 S-555739 (prostaglandin D2 receptor antagonist) - Shionogi 10.5.2 DSP-3025/AZD-8848 (toll-like receptor 7 agonist) - Dainippon Sumitomo/ AstraZeneca 10.5.3 GSK2245035 (toll-like receptor 7 agonist) - GSK 10.5.4 HP-3060 (transdermal long-acting tape) - Hisamitsu 10.5.5 MRX-4 (anti-inflammatory agent) - Celsus Therapeutics 11. Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2016-2026 11.1 Market Factors Influencing Allergic Rhinitis Drugs 11.2 SWOT Analysis Of The Global Allergic Rhinitis Drugs Market, 2016-2026 11.2.1 Strengths 11.2.1.1 OTC-Switch Facilitating Ease Of Consumer Access 11.2.1.2 The Established Role Of Allergic Rhinitis Drugs In Treatment 11.Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2016-2026
- 13. www.visiongain.com Contents 11.2.1.3 Allergic Rhinitis And The Rising Unmet Clinical Need 11.2.1.4 Rising Profile of Allergic Rhinitis In Various Regions Driving Healthcare Provision 11.2.2 Weaknesses 11.2.2.1 Intranasal Corticosteroids And Patients’ Satisfaction Rates 11.2.2.2 Increasing Penetration Of Generic Drug Products 11.2.2.3 The Challenge Raised By The Low Volume Of Pipeline Developments 11.2.3 Opportunities 11.2.3.1 Growth In Emerging Markets Outstripping Established Markets 11.2.3.2 Rx-to-OTC Switching And The Effects On Revenue Potential 11.2.3.3 Combination Drug Products Providing Rising Efficacy Profiles 11.2.3.4 The Emergence Of Immunotherapy In Allergic Rhinitis 11.2.4 Threats 11.2.4.1 Cost-Containment As A Growth Restraint 11.2.4.2 Rising Cost Of APIs And Manufacturing 11.2.4.3 Patent Expiries And The Resultant Loss Of Revenue 11.3 Porter’s Five Force Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2026 11.3.1 Power of Buyers 11.3.2 Power Of Suppliers 11.3.3 Threat of Substitutes 11.3.4 Threat Of New Entrants 11.3.5 Rivalry Among Competitors
- 14. www.visiongain.com Contents 12. Conclusions 12.1 Overview of Current Market Conditions and Market Forecast, 2015-2026 12.2 Leading Sectors in the Allergic Rhinitis Drugs Market in 2015 12.3 Leading Regions in the Allergic Rhinitis Drugs Market in 2015 12.4 Leading Companies in the Allergic Rhinitis Drugs Market, 2015 12.5 What Does The Future Hold For Allergic Rhinitis Drugs? 12.Conclusions
- 15. www.visiongain.com Page 55 Allergic Rhinitis Drugs Market Forecast 2016-2026 Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. Corticosteroids have a delayed onset of action in allergic rhinitis (by a few days) compared to antihistamines, which can be effective within 1-2 hours. It may take several days of treatment to achieve full benefit from a corticosteroid spray, and conversely, symptoms may not return for several days after a corticosteroid is discontinued. 2.4.2.1 First-, Second- And Third-Generation Intranasal Corticosteroids Intranasal steroids are divided into three generations depending on their bioavailability (Table 2.2). First-generation corticosteroids (e.g. beclometasone and triamcinolone) have higher bioavailability (40-50%) and tend to produce more systemic side-effects. Second- and third-generation corticosteroids have lower bioavailability (10-30% for second-generation, <2% for third-generation) and limited systemic side-effects. Studies of second- and third-generation intranasal steroids at recommended doses have found no effect or limited effects on growth in children. Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2016 2.4.2.2 Combination Drug Products Combination drug products allow a single product to combine the benefits of multiple active ingredients and are particularly useful in allergic rhinitis. The main combinations comprise oral antihistamines combined with a decongestant, and an intranasal corticosteroid combined with an intranasal antihistamine. Examples of the former include Claritin-D 24 Hour (loratadine and pseudoephedrine, Merck & Co.) and Allegra-D (fexofenadine and pseudoephedrine, Sanofi). The leading example of the latter is Dymista (azelastine and fluticasone propionate, Meda). Drug Description Manufacturer Beconase AQ (beclometasone dipropionate) First-generation corticosteroid GSK/Omega Pharma Nasacort AQ (triamcinolone acetonide) First-generation corticosteroid Sanofi Rhinocort Aqua (budesonide) Second-generation corticosteroid AstraZeneca Flonase (fluticasone propionate) Third-generation corticosteroid GSK Nasonex (mometasone furoate) Third-generation corticosteroid Merck & Co. Omnaris (ciclesonide) Third-generation corticosteroid Takeda/Dainippon Sumitomo Veramyst (fluticasone furoate) Third-generation corticosteroid GSK Source: visiongain 2016
- 16. www.visiongain.com Page 179 Allergic Rhinitis Drugs Market Forecast 2016-2026 Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. 8.9.3 Indian Allergic Rhinitis Drugs Market: Market Forecast 2016-2026 Despite a prevalence of over 20% and a rapidly expanding population, allergic rhinitis remains under-treated in India. Air pollution in cities has been linked to the growing prevalence of allergic rhinitis in India. The increasing healthcare coverage and economic growth are also expected to drive demand for intranasal allergic rhinitis drugs in the country. However, we note that the market is highly competitive, with many generic manufacturers producing generic versions of leading brands and recent price control measures have put further downward pressure on drug prices. Visiongain has estimated the Indian allergic rhinitis drugs market at $270m in 2015 (Table 8.16 and Figure 8.18). We forecast this market to rise to $511m in 2020, with a CAGR of 13.6% between 2015 and 2020 (Table 8.16 and Figure 8.18). We expect the increase in prevalence of allergic rhinitis and the expanding healthcare coverage in the country to help to boost the allergic rhinitis drugs market in India over the latter part of the forecast period. We forecast this market to grow to $1,011 in 2026, having risen with a CAGR of 12.1% between 2020 and 2026 (Table 8.16 and Figure 8.18). Table 8.16 and Figure 8.18 show visiongain’s forecast for the Indian allergic rhinitis drugs market over 2015-2026. Table 8.16 Indian Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 IndiaRevenue($m) 270 308 349 393 448 511 576 655 731 814 886 1,011 AnnualGrowth(%) 14.3 13.0 12.8 13.9 13.9 12.9 13.6 11.6 11.3 8.9 14.1 CAGR(%,2015-2020&2020-2026) CAGR(%,2015-2026) 13.6 12.1 12.8 Source: visiongain 2016
- 17. www.visiongain.com Page 198 Allergic Rhinitis Drugs Market Forecast 2016-2026 Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. rhinitis drugs. However, patent expiry for its big selling Nasonex and the sale of its Claritin OTC franchise to Bayer is expected to cause Merck’s allergic rhinitis drugs sales to decline steeply over the forecast period. Table 9.10 provides an overview of Merck’s current business in 2016. Table 9.10 Merck & Co: Company Overview, 2016 Company Merck & Co., Inch (Merck) Notable Subsidiaries Schering-Plough (2009), Inspire Pharmaceuticals (2001) Business Areas Pharmaceuticals, Consumer Healthcare, Vaccines, Animal Health Established 1917 (initially in 1891, the US subsidary of Merck KGaA) Headquarters Whitehouse Station, New Jersey, US FY2015 Revenue ($bn) 39.5 We note that the similarly-named but separate company Merck Group is also a player in the allergic rhinitis market; we refer to Merck & Co. as ‘Merck’ and refer to Merck Group as ‘Merck Group’ or ‘Merck-Serono’. 9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2016 Merck’s allergic rhinitis drugs portfolio in 2016 consisted of the following major products: • Clarinex (desloratadine), a newer oral antihistamine (Chapter 4) Source: visiongain 2016; Merck 2016